Document Detail


Stevens-Johnson syndrome induced by acetazolamide.
MedLine Citation:
PMID:  21342230     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Acetazolamide is a sulfonamide derivative and carbonic anhydrase inhibitor used to lower intraocular pressure in glaucomatous patients. Stevens-Johnson syndrome (SJS) toxic epidermal necrolysis (TEN) associated with acetazolamide treatment has been diagnosed in Japanese, Japanese-American and Indian patients. Herein, we report the second Korean case of SJS-TEN associated with acetazolamide treatment. The result of human leukocyte antigen (HLA) typing of our patient was positive for HLA-B59. According to recent research, HLA-B59 has been detected in SJS caused by metazolamide, which is analogous to acetazolamide. This suggests a possible relationship between genetic background and SJS-TEN-associated acetazolamide treatment. Theretofore, acetazolamide should be prescribed to Korean patients with the same discreet caution.
Authors:
Young Her; Min S Kil; Ju H Park; Chul W Kim; Sang S Kim
Publication Detail:
Type:  Journal Article     Date:  2010-12-13
Journal Detail:
Title:  The Journal of dermatology     Volume:  38     ISSN:  1346-8138     ISO Abbreviation:  J. Dermatol.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600545     Medline TA:  J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  272-5     Citation Subset:  IM    
Copyright Information:
© 2010 Japanese Dermatological Association.
Affiliation:
Department of Dermatology, College of Medicine, Hallym University, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metal patch test results from 1990-2009.
Next Document:  Allergic contact dermatitis due to diclofenac sodium in eye drops.